Please login to the form below

Not currently logged in
Email:
Password:

Gilead's John Martin steps down as chief executive officer

He becomes executive chairman and is replaced as CEO by John Milligan 

Gilead John MartinGilead Sciences' John Martin has stepped down as chief executive officer, a role he had held since 1996, and moved to a new role as executive chairman.

His replacement as CEO is John Milligan who joined Gilead in 1990 as a research scientist and has since held several senior management positions at the company including chief financial officer.

Martin (pictured above) started at Gilead in 1990 as vice president for research and development and has 40 years of pharmaceutical and management expertise, during which he spent time in several leadership positions at Bristol-Myers Squibb and Syntex.

He was made chairman of Gilead's board in 2008 and will now transition from CEO and chair to executive chairman over the next six weeks.

John Cogan, Gilead's lead independent director, said: “John Martin has led Gilead as chief executive officer for the past 20 years, and under his stewardship, the company has developed and delivered therapeutic advancements to millions of people around the world.

“His legacy is clear - and the vision he has set will continue with his contributions as executive chairman.”

Gilead John MilliganTaking the reins from Martin at the California-based biopharmaceutical company is John Milligan (pictured left), who currently serves as its president and chief operating officer.

Milligan will become Gilead's chief executive officer on 10 March, when he will also join the firm's board of directors.

John Martin said: “Over the past 25 years, John Milligan has distinguished himself as an exceptional leader, serving in diverse management roles and overseeing multiple phases of growth and expansion into new therapeutic areas and geographies.

“The board of directors and I are confident in his ability to lead Gilead into the future.”

3rd February 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics